scholarly journals A rare localization of tuberculosis under infliximab treatment: Testicular involvement

2021 ◽  
Vol 67 (3) ◽  
pp. 374-377
Author(s):  
Mehmet Nayımoğlu ◽  
Banu Sarıfakıoğlu ◽  
Kübra Ustaömer ◽  
Murat Akgül ◽  
Ayşegül Isal Arslan
Keyword(s):  
Side Effects ◽  
Latent Tuberculosis Infection ◽  
Latent Tuberculosis ◽  
Demyelinating Diseases ◽  
Infliximab Treatment ◽  
Necrosis Factor Alpha ◽  
Inflammatory Bowel ◽  
Factor Alpha ◽  
Extra Pulmonary ◽  
Necrosis Factor

Infliximab is an inhibitory of tumor necrosis factor-alpha which is used successfully for the treatment of inflammatory bowel disease and rheumatic disease. It has various side effects including injection-induced reactions, immunosuppression, demyelinating diseases, and cardiac effects. One of the most serious side effects is tuberculosis. In particular, the immunosuppressant drugs have a high risk of reactivating latent tuberculosis infection. Its activation probably may occur as an extra-pulmonary and, occasionally, may result in an unusual infection. Herein, we report a 30-year-old male case treated with infliximab and suffered from isolated testicular tuberculosis.

scholarly journals Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test

Pathogens ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 535
Author(s):  
Anna Colombo ◽  
Mauro Giuffrè ◽  
Lory Saveria Crocè ◽  
Sergio Venturini ◽  
Renato Sablich
Keyword(s):  
Ulcerative Colitis ◽  
Latent Tuberculosis ◽  
Infliximab Treatment ◽  
Necrosis Factor Alpha ◽  
Tnf Α ◽  
Current Controversy ◽  
Latent Tb ◽  
Factor Alpha ◽  
Necrosis Factor ◽  
Quantiferon Test

Infliximab is an IgG1 antitumor necrosis factor monoclonal antibody that is commonly used to treat inflammatory bowel disease (IBD) and other autoimmune disorders. However, it is known to increase the risk of reactivation of latent tuberculosis (LTBI) due to its capability to disrupt TB granulomas. We describe a case of extrapulmonary TB in a patient with ulcerative colitis who was treated with Infliximab after a negative Quantiferon Test. In addition, we report briefly on the current controversy about the appropriateness, interval, and methods for the repeated screening of latent TB in IBD patients that are treated with antitumor necrosis factor alpha (TNF-α) antibodies.

scholarly journals Pathological findings in central nervous system demyelination associated with infliximab

2019 ◽  
Vol 26 (9) ◽  
pp. 1124-1129 ◽  
Author(s):  
Alicja Kalinowska-Lyszczarz ◽  
Mahboobeh Fereidan-Esfahani ◽  
Yong Guo ◽  
Claudia F Lucchinetti ◽  
W Oliver Tobin
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Tnf Alpha ◽  
Infliximab Treatment ◽  
Necrosis Factor Alpha ◽  
Immune Mediated ◽  
Central Nervous System Demyelination ◽  
Factor Alpha ◽  
Cns Demyelination ◽  
Necrosis Factor

Background: Tumor necrosis factor alpha (TNF-alpha) inhibitors, such as infliximab, are commonly used to treat rheumatoid arthritis (RA) and other immune-mediated disorders. Objective: To determine whether infliximab-associated central nervous system (CNS) demyelination can be differentiated from multiple sclerosis (MS). Methods: We present a case of pathologically proven CNS demyelination in a patient treated with infliximab and describe clinical–radiographic–neuropathological findings. Putative mechanisms of TNF-alpha inhibitor-associated CNS demyelination are described. Results and conclusion: Infliximab treatment is associated with CNS inflammatory demyelinating activity, which is histopathologically indistinguishable from MS.

Sign in / Sign up

Export Citation Format

Share Document